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Abstract – A method aiming at investigating possible bioactive conformations of acyl 
homoserine lactone (AHL) quorum sensing (QS) modulators is established. The method relies on 
the exhaustive conformational analysis of AHLs by varying torsion angles around the amide 
group then on the selection of the closest conformation to those known from co-crystallized XRD 
data of AHL-receptor complexes. These latter are then docked as rigid ligand within the receptor 
binding site, leading to conformations, interactions with binding site residues which are highly 
consistent as compared with the data arising from XRD studies.  
The method is first validated using AHLs for which XRD data of their complexes with their 
cognate receptor are available, then extended to examples for which the binding mode is still 
unknown.  
Three compounds were used to validate the method: hexanoyl homoserine lactone (HHL) as an 
example of autoinducer, 3-oxo-butanoyl homoserine lactone (OBHL), as a representative model 
of 3-oxo-AHLs, and 4-(4-chlorophenoxy)butanoyl homoserine lactone (CPOBHL) as an example 
of a QS inhibitor. The conformational analysis of these three compounds to their cognate protein 
(TraR, SdiA, LasR and CviR) provides the data which enable the next rigid docking step. Further 
rigid docking of the closest conformations compared to the known bioactive ones within the 
binding sites allows to recover the expected binding mode with high precision (atomic RMSD < 
2Å). This “conformational analysis/torsion angle filter/rigid ligand docking” method was then 
used for investigating three non-natural AHL-type QS inhibitors without known co-crystallized 
XRD structures, namely was 2-hexenoyl homoserine lactone (HenHL), 3-oxo-4-phenylbutanoyl 
homoserine lactone (OPBHL) and 3-(4-bromophenyl)propanoyl homoserine lactone (BPPHL). 
Results provide insights into their possible binding mode by identifying specific interactions with 
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some key residues within the receptor binding site, allowing discussion of their biological 
activity.  
Key words: Conformational analysis, Acyl homoserine lactone, Quorum sensing, Docking 
 
1. Introduction 
Acyl homoserine lactones (AHLs) are used by Gram negative bacteria to communicate in order 
to synchronize their behavior according to their environment. AHLs, referred to as autoinducers, 
are biosynthesized by proteins of the LuxI family, and known to bind transcriptional regulator of 
the LuxR family.[1, 2] This system called quorum sensing is extensively studied, especially to 
interfere with bacterial communication.[3-5] The structure of AHLs differs according to bacteria 
species, with different alkyl chain lengths, and presence or not of a 3-oxo functional group. For 
example, 3-oxo-hexanoyl homoserine lactone (OHHL) is found in Vibrio fischeri (recognized by 
luxR), 3-oxo-octanoyl homoserine lactone (OOHL) in Agrobacterium fabrum previously referred 
to as Agrobacterium tumefaciens (recognized by TraR), 3-oxo-dodecanoyl homoserine lactone 
(ODHL) in Pseudomonas aeruginosa (recognized by LasR) and hexanoyl homoserine lactone 
(HHL) in Chromobacterium violaceum (recognized by CviR).  
The molecular structure of AHL can be divided in three blocks: block 1, the lactone moiety; 
block 2, the 3-oxo amide functional group; and block 3, the alkyl chain.[6]  
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In terms of conformation of homoserine lactones,[7-10] conformational analysis studies have 
shown that they can adopt different conformations depending on the occurrence or not of a n→π* 
interaction between p-type lone pair (n) of the N-acyl oxygen of the amide with the π* orbital of 
the lactone carbonyl functional group. Notably the study by Raines and co-workers using DFT 
calculations showed particularly the importance of this n→π* interaction for free AHLs whereas 
for bound conformations this interaction do not exist.[8] The importance of the solvents effects 
was further highlighted by the study by Kelleher and co-workers who showed, also using DFT 
calculations, that n→π* interactions become stronger with the polarity of the solvent.[9, 10] 
All functional groups found in AHLs and their close analogues are known to influence their 
molecular recognition by their cognate receptors, through hydrogen bonds and hydrophobic 
interactions. As example, the XRD data for the complex between OOHL and TraR (pdb code 
1L3L)[11] shows that the lactone is involved in a hydrogen bond with Trp57, the amide with 
Asp70 (NH) and Tyr53 (C=O), and the 3-oxo functional group with a water molecule (Fig. 1). 
Similar binding modes are obtained from X-ray structures of SdiA in complex with 3-oxo-
hexanoyl homoserine lactone (OHHL) and 3-oxo-octanoyl homoserine lactone (OOHL) (pdb 
code 4Y15 and 4Y17),[12] and of LasR with 3-oxo-dodecanoyl homoserine lactone (ODHL) 
(pdb code 3IX3). For the complex of CviR and the native ligand hexanoyl homoserine lactone 
(HHL) lactone (pdb code 3QP1),[13] the same overall binding mode was observed, except the 
hydrogen bond with the water molecule due to the absence of the 3-oxo functional group. For the 
inhibitor 4-(4-chlorophenoxy)butanoyl homoserine lactone (CPOBHL) in complex with CviR 
(pdb code 3QP5), a similar hydrogen bond network is observed (the lactone and Trp84 and the 
amide with Asp97 (NH) and Tyr80 (C=O)) as well as aromatic interactions between the 4-
chlorophenyl substituent and Tyr88 (Fig. 1).[13] 
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In this work, using XRD data from six co-crystallized AHLs-proteins complexes, representative 
of the structural diversity of AHLs and of the receptors, we developed a “conformational 
analysis/torsion angle filter/rigid ligand docking” method which was then applied to AHL-type 
QS inhibitors for which no XRD data support any binding mode. Technically, three compounds 
were used for the first validation phase, namely hexanoyl homoserine lactone (HHL) as an 
example of 3-CH2 AHL autoinducer, 3-oxo-butanoyl homoserine lactone (OBHL) a 
representative model example of natural 3-oxo AHLs, and the known QS inhibitor 4-(4-
chlorophenoxy)butanoyl homoserine lactone (CPOBHL) as example of AHL analogue modified 
on the side chain. The method was then applied in a second phase using three AHL-type QS 
modulators with unreported XRD data reflecting the same structural diversity, namely TraR 
antagonist 2-hexenoyl homoserine lactone (HenHL), as example of close analog of AHL,[14, 15], 
3-oxo-4-phenylbutanoyl homoserine lactone (OPBHL), as an example of 3-oxo-AHL analog, and 
the interesting broad spectrum antagonist[16, 17] 3-(4-bromophenyl)propanoyl homoserine 
lactone (BPPHL) as example of aromatic AHL analog. 
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Figure 1: Bound (bioactive) conformations (cyan) of acylhomoserine lactones: 3-oxo-hexanoyl 
homoserine lactone (SdiA pdb 4Y15), hexanoyl homoserine lactone (CviR pdb 3QP1), 3-oxo-
octanoyl homoserine lactone (TraR pdb 1L3L and SdiA pdb 4Y17), 3-oxo-dodecanoyl 
homoserine lactone (LasR pdb 3IX3) and 4-(4-chlorophenoxy)butanoyl homoserine lactone 
(CviR pdb 3QP5). 
 
2. Computational methods 
For conformational analyses,[7] the three compounds, hexanoyl homoserine lactone (HHL), 3-
oxo-butanoyl homoserine lactone (OBHL) and 4-(4-chlorophenoxy)butanoyl homoserine lactone 
(CPOBHL) were constructed using Vega ZZ[18, 19], and charges were assigned with the SP4 
force field and Gasteiger.[20] The obtained 3D models were then subjected to a systematic 
conformational search[21-24] with the implemented AMMP program[25] (SP4 force field) by 
varying five torsion angles using a 60° increment (7776 conformations) for HHL, three torsion 
angles using a 30° increment (1728 conformations) for OBHL and six torsion angles using a 60° 
increment (46656 conformations) for CPOBHL (in all cases, the amide bond is in s-trans 
conformation). Increments of 30° or 60° in torsion angles were chosen for keeping the method 
practical in terms of calculation time and number of generated data. Indeed, for compounds that 
require variations of 3 or 4 torsion angles, an increment of 30° lead to 1728 or 20736 
conformations respectively, which is easily analyzed, whereas for 5 or 6 torsion angles, 30° 
would lead to 248832 or 2985984 conformations, respectively, less appropriate for next steps of 
the method. In those cases, an increment of 60° was preferred , leading to 7776 or 46656 
conformations, respectively, though leading to meaningful docking results as measured by low 
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RMSD value < 2 Å.[26] For OBHL which is a 3-oxo amide, the method was performed on its 3-
oxo tautomeric forms, the most predominant form,[9] rather than on the enol tautomeric one. The 
generated conformations were then analyzed to define the most stable ones for the three 
compounds, and the closest conformations as compared with the known bound conformations to 
TraR, SdiA, LasR or CviR (pdb codes 1L3L, 4Y15, 4Y17, 3IX3, 3QP1 and 3QP5) were selected. 
These latter were then docked as rigid ligands within their cognate receptor binding site using 
Arguslab[27] with the following parameters: Docking box: X = Y = Z = 15 Å, ligand option: 
rigid; calculation type: Dock; Docking engine: GADock (Genetic Algorithm);[28] Genetic 
algorithm dock settings: default advanced parameters. The “conformational analysis/torsion angle 
filter/rigid ligand docking” method was then applied to three examples for which no X-ray data is 
available, HenHL, OPBHL and BPPHL. For HenHL and BPPHL, the method was executed using 
four torsion angles with 30° increments which led to 20736 conformations. For OPBHL, five 
torsion angles and 60° increments were used, leading to 7776 conformations.  
 
3. Results and discussion 
Docking experiments with stochastic genetic algorithm frequently give different binding modes 
rendering difficult their validation.[29, 30] As a consequence, conformational and docking 
studies were first applied to AHLs which have been co-crystallized with transcriptional factor of 
the LuxR family namely TraR, SdiA, LasR or CviR in order to validate the method i.e. to retrieve 
the co-crystallized conformation. The method, validated with co-crystallized AHLs was then 
applied to AHLs with unknown binding mode from XRD data (Figure 2).  
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Figure 2: Description of the “conformational analysis/torsion angle filter/rigid ligand docking” 
method. 
 
Conformational analyses of HHL, OBHL and CPOBHL were thus achieved by varying key 
torsion angles defined by the atoms marked in bold. For OBHL, an increment of 30° for the three 
torsion angles was chosen to generate 1728 conformations. For HHL and CPOBHL, an increment 
of 60° was selected to limit the number of conformations to 7776 and 46656 respectively. 
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3.1. Conformational analysis and docking studies of AHLs with known XRD data 
3.1.1. Hexanoyl homoserine lactone (HHL) 
Among the 7776 conformations generated for HHL, the most stable conformation was obtained 
with a calculated energy value of 21 kcal.mol-1. To retrieve the bound conformation of HHL in 
complex with CviR, ω1 to ω5 were measured and the conformation with closest torsion angle 
values was selected. The conformation 6106 was recovered for its similarity in the key angles as 
compared to the known bound conformer (Table 1). These two conformations (the lowest energy 
conformation and the conformation 6106) are very close in energy (only 1 kcal/mol different) 
though dissimilar in terms of torsion angles values. No n→π* interaction, known to be observed 
preferentially for non-bound AHLs [8, 10] was observed here logically, as only “bound-like” 
conformations are selected during the protocol.  
Table 1. HHL: values in degree of the torsion angles for the most stable, the bound conformation and the closest 
conformation (energy in kcal/mol) 
 ω1 ω2 ω3 ω4 ω5 energy 
Lowest (4162) 180 60 60 180 180 21 
Bound (CviR) 240 240 70 150 150 -- 
6106 240 240 60 180 180 22 
 
A rigid docking was then applied to the conformation 6106 within the binding site of CviR 
(Figure 3). The conformation 6106 fits very well with a RMSD value of 0.84 Å[26] showing the 
robustness of the method using conformational search and subsequent rigid ligand docking. 
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Figure 3: Rigid ligand docking result of HHL within the binding site of CviR (co-crystallized 
conformation is colored in cyan and conformation 6106 in magenta). 
 
3.1.2. 3-Oxo-butanoyl homoserine lactone (OBHL)  
3-Oxo-butanoyl homoserine lactone (OBHL) was chosen as a representative example of 3-oxo 
homoserine lactones, possessing the key 3-oxo functional group known to be involved in 
additional H-bonds with a water molecule. In the family of 3-oxo-AHLs, the butyl analog (C4) 
was chosen because it is long enough to mimic longer alkyl chains, which only differ at the side-
chain extremity with successive anti or gauche relationships for each additional C-C bond (as 
shown for HHL), though not modifying the main lactone-amide-3-oxo overall conformation.[7] 
Therefore, using OBHL in our study is the way to access the key ω1 to ω3 angles during the 
conformational analysis, while keeping practical both the calculation time and data analysis. This 
choice is validated by the consistency of the docking results (see below) with known XRD data 
for short or longer 3-oxo-AHLs. 
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Among the 1728 conformations generated, the most stable one was obtained with an energy value 
of 10 kcal.mol-1. To retrieve the bound conformation of OBHL in complex with TraR, SdiA and 
LasR, ω1 to ω3 were measured, and the conformations with closest torsion angle values 
compared to those of the bound compounds were selected. Thus, conformations 1263 for TraR, 
1251 for the C6-type SdiA, 1371 for C-8-type SdiA and 1267 for LasR in complex with 3-oxo-
dodecanoyl homoserine lactone were selected (Table 2). 
Table 2. OBHL: values in degree of the torsion angles for the most stable and the bound conformations and the 
closest conformations (energy in kcal/mol) 
 ω1 ω2 ω3 energy RMSD 
Lowest (1037) 210 60 120 10 -- 
Bound (TraR) 250 260 54  -- -- 
1263 240 270 60 22 0.76 
Bound (SdiA 4Y15) 245 245 90 -- -- 
1251 240 240 90 12 1.14 
Bound (SdiA 4Y17)) 260 190 90 -- -- 
1372 270 180 90 24 1.31 
Bound (LasR) 240 260 190 -- -- 
1267 240 270 180 25 0.99 
 
A rigid docking was then applied to the four selected conformations within the binding site of the 
three corresponding proteins (Figure 4). The conformations of the bound OBHL overlap very 
well with those of the native autoinducers, with RMSD values ranging from 0.76 to 1.31 Å when 
comparing the common part of the molecules showing the robustness of the method and 
confirming that the C-4 derivative is a meaningful model for longer chains (Table 2). 
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Figure 4: Rigid ligand docking results of the selected conformations for OBHL within the 
binding site of TraR, SdiA and LasR. (The co-crystallized conformations with OOHL, OHHL, 
ODHL are colored in cyan)  
 
3.1.3. 4-(4-Chlorophenoxy)butanoyl homoserine lactone (CPOBHL) 
Finally, we performed the study of the QS inhibitor CPOBHL which has been co-crystallized 
with CviR. The six torsion angles were subjected to a systematic conformational search by 
varying with a 60° increment generating 46656 conformations. To retrieve the bioactive 
conformation, the 6 torsion angles were estimated for the known bound conformation (table 3). In 
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this case, three conformations of CPOBHL showing similar structural closeness to the known 
bound conformation were selected, i.e. conformations 36633, 36591 and 36597 (table 3).  
 
Table 3. CPOBHL: values in degree of the torsion angles for the most stable, the bound conformation and the closest 
conformations (energy in kcal/mol) 
 ω1 ω2 ω3 ω4 ω5 ω6 energy RMSD 
Lowest (27203) 180 120 300 300 180 240 30 -- 
Bound (CviR) 250 240 60 146 150 136 -- -- 
36633 240 240 60 180 180 120 35 1.78 
36591 240 240 60 120 120 120 39 1.84 
36597 240 240 60 120 180 120 39 1.16 
 
The selected conformations were then docked as rigid ligands within the binding site of CviR 
(Figure 5). All conformations fit well (RMSD < 2 Å) with the best docking result obtained for the 
conformation 36597 (yellow conformation). 
 
15 
 
Figure 5: Rigid ligand docking results of selected conformations of OBHL within the binding site 
of CviR (magenta 36591, brown 36633, yellow 36597 and cyan co-crystallized conformation). 
 
3.2. Application to AHLs without known XRD data  
3.2.1. 2-Hexenoyl homoserine lactone (HenHL) 
 
Having the protocol validated by the above results, we applied it for investigating the possible 
binding mode of 2-hexenoyl homoserine lactone (HenHL), a TraR antagonist [14, 15] for which 
no binding mode has been shown. After conformational analysis, the closest torsion angles values 
as compared to the natural ligand were selected for rigid ligand docking experiments. The 
retained conformation 14779 exhibits a rigid planar system in s-trans conformation for the 
conjugated double bond with the carbonyl of the amide functional group (Table 4).  
 
Table 4. HenHL: values in degree of the torsion angles for the most stable and the closest conformation compared to 
the natural ligand (energy in kcal/mol) 
 ω1 ω2 ω3 ω4 energy 
Lowest (11347) 180 180 270 180 20 
Closest (14779) 240 180 210 180 24 
 
Next, the rigid ligand docking experiment showed that the rigidity of the alkenyl chain due to the 
planarity of the enamide moiety induces a different orientation of the acyl chain in the 
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hydrophobic zone of the binding site compared to the TraR autoinducer OOHL, while the 
hydrogen bonds network remains the same. The particular orientation of the acyl chain leads to 
new hydrophobic interactions between the enamide functional group and Tyr61, not seen in the 
case of the OOHL binding mode, which may explain the antagonistic activity of this compound 
(Figure 6).  
 
 
Figure 6: Rigid ligand docking result for 2-hexenoyl homoserine lactone (HenHL), (magenta) 
within the binding site of TraR. The co-crystallized natural ligand is colored in cyan. 
 
3.2.2. 3-Oxo-4-phenylbutanoyl homoserine lactone (OPBHL) 
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Among 3-oxo-AHL analogues, the method was then applied to 3-oxo-4-phenylbutanoyl 
homoserine lactone (OPBHL), a very potent TraR antagonist with a 3-oxo functional group.[16] 
The conformational analysis allowed to select the closest conformation as compared to the TraR 
natural ligand (Table 5). 
Table 5. OPBHL: values in degree of the torsion angles for the most stable and the closest conformations compared 
to the natural ligand (energy in kcal/mol) 
 ω1 ω2 ω3 ω4 ω5 energy 
Natural ligand 250 260 54 220 180 -- 
Lowest (4256) 180 60 240 60 60 15 
Closest (6112) 240 240 60 240 180 25 
 
The retained conformation 6112 was then submitted to rigid ligand docking within the binding 
site of TraR. The rigid ligand docking result shows that this compound fits very well within the 
TraR binding site. The overall orientation of the molecule is similar compared to the native 
ligand (in cyan) with a comparable hydrogen bond network, but new attractive interactions with 
Tyr53 and Tyr61 of the phenyl group are clearly observed (Figure 7). These attractive 
interactions appear as sensible causes for explaining the potent antagonistic activity of this 
compound.  
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Figure 7: Rigid ligand docking result of the selected conformation for 3-oxo-4-phenylbutanoyl 
homoserine lactone (OPBHL) within the binding site of TraR (magenta 6112 and cyan co-
crystallized conformation of 3-oxo-octanoyl homoserine lactone). 
 
3.2.3. 3-(4-Bromophenyl)propanoyl homoserine lactone (BPPHL) 
 
Finally, the interesting broad spectrum antagonist 3-(4-bromophenyl)propanoyl homoserine 
lactone (BPPHL) [16, 17] was investigated through the same protocol as above. Conformational 
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analysis was performed and two close conformations as compared to the natural ligand were 
selected, namely conformations 15152 and 15153 (Table 6). 
Table 6. BPPHL: values in degree of the torsion angles for the most stable and the closest conformations compared 
to the natural ligand (energy in kcal/mol) 
 ω1 ω2 ω3 ω4 energy 
Natural ligand 250 260 54 220 -- 
Lowest (13474) 210 270 180 270 30 
Closest (15152) 240 270 60 210 31 
Closest (15153) 240 270 60 240 43 
 
The retained conformations 15152 and 15153 were then submitted to rigid ligand docking within 
the binding site of TraR as reference protein. Results reveal a similar overall orientation as 
compared to the natural ligand but with significant differences in several interactions. While the 
hydrogen bonds involving the NH and the carbonyl of the amide functional group with Asp70 
and Tyr53 are conserved, the carbonyl of the lactone is deprived of the hydrogen bond with 
Trp57 and the intra-cyclic oxygen of the lactone is involved in a hydrogen bond with this residue. 
On the chain side, the 3-(4-bromophenyl)propanoyl chain induces attractive interactions with 
Tyr53 and Tyr61. These attractive interactions and this new hydrogen network can be considered 
as possible causes for explaining the antagonistic activity of this compound (Figure 8).  
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Figure 8: Rigid ligand docking results of selected conformations for 3-(4-bromophenyl)propanoyl  
homoserine lactone (BPPHL) within the binding site of TraR (yellow 15152, magenta 15153 and 
cyan co-crystallized conformation of 3-oxo-octanoyl homoserine lactone). 
 
4. Conclusion 
A method based on conformation analyses, torsion angle filter and subsequent rigid ligand 
docking experiments has been applied to AHLs and analogues to investigate bioactive 
conformations. This method allows the data for the conformations recognized by their cognate 
transcriptional regulator to be retrieved, ready to be used as starting files for the subsequent rigid 
ligand docking experiments. This latter step led to low RMSD values indicating the robustness of 
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the method. The proposed protocol shows excellent consistency between calculation and X-ray 
structural data.  
The method allowed to investigate the putative binding mode of three AHL-type QS inhibitors 
analogues for which no X-ray data is available. For 2-hexenoyl homoserine lactone and 3-oxo-4-
phenylbutanoyl homoserine lactone, new interactions in the hydrophobic zone are observed, and 
and for broad spectrum QS inhibitor 3-(4-bromophenyl)propanoyl homoserine lactone, attractive 
interactions for the side chain and a different hydrogen network on the lactone-amide moiety 
have been found. By providing insights in the modes of action of reported QS modulators, the 
present method can therefore be considered as a complementary tool in studies directed to the 
design of new AHL analogues as QS modulators. 
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